Publication:
Development of NIRS method for quality control of drug combination artesunate-azithromycin for the treatment of severe malaria

dc.contributor.authorChantal Boyeren_US
dc.contributor.authorKaren Gaudinen_US
dc.contributor.authorTina Kaussen_US
dc.contributor.authorAlexandra Gauberten_US
dc.contributor.authorAbdelhakim Boudisen_US
dc.contributor.authorJustine Verscheldenen_US
dc.contributor.authorMickaël Francen_US
dc.contributor.authorJulie Roussilleen_US
dc.contributor.authorJacques Boucheren_US
dc.contributor.authorPiero Olliaroen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorPascal Milleten_US
dc.contributor.authorJean Pierre Dubosten_US
dc.contributor.otherDeveloppements Analytiques et Pharmaceutiques Appliques aux Maladies Negligees et Aux Contrefaconsen_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Oxforden_US
dc.date.accessioned2018-06-11T04:35:00Z
dc.date.available2018-06-11T04:35:00Z
dc.date.issued2012-08-01en_US
dc.description.abstractNear infrared spectroscopy (NIRS) methods were developed for the determination of analytical content of an antimalarial-antibiotic (artesunate and azithromycin) co-formulation in hard gelatin capsule (HGC). The NIRS consists of pre-processing treatment of spectra (raw spectra and first-derivation of two spectral zones), a unique principal component analysis model to ensure the specificity and then two partial least-squares regression models for the determination content of each active pharmaceutical ingredient. The NIRS methods were developed and validated with no reference method, since the manufacturing process of HGC is basically mixed excipients with active pharmaceutical ingredients. The accuracy profiles showed β-expectation tolerance limits within the acceptance limits (±5%). The analytical control approach performed by reversed phase (HPLC) required two different methods involving two different preparation and chromatographic methods. NIRS offers advantages in terms of lower costs of equipment and procedures, time saving, environmentally friendly. © 2012 Elsevier B.V.en_US
dc.identifier.citationJournal of Pharmaceutical and Biomedical Analysis. Vol.67-68, (2012), 10-15en_US
dc.identifier.doi10.1016/j.jpba.2012.04.009en_US
dc.identifier.issn1873264Xen_US
dc.identifier.issn07317085en_US
dc.identifier.other2-s2.0-84862116212en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/13655
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862116212&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemistryen_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleDevelopment of NIRS method for quality control of drug combination artesunate-azithromycin for the treatment of severe malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862116212&origin=inwarden_US

Files

Collections